Trial Profile
Bendamustine, Bortezomib and Dexamethasone (BVD) in the treatment of relapsed or refractory Multiple Myeloma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2015
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 18 Jul 2011 New trial record